Teva to present new data on Austedo tablets at Psych congress 2019
October 2, 2019Three new presentations evaluate Austedo tablets for the treatment of tardive dyskinesia in adults
JERUSALEM & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
Presentations include an additional analysis of AIMS Global Judgment Components (Items 8-10) in the pivotal ARM-TD and AIM-TD studies that evaluated AUSTEDO tablets for the treatment of tardive dyskinesia (TD) in adults; an analysis of the effect of AUSTEDO on metabolic parameters in the treatment of TD in the pivotal studies as well as the ongoing long-term study; and an analysis of the randomized withdrawal study design that evaluated the persistence of the therapeutic effect of AUSTEDO in TD. Additional data include two presentations showcasing the results from the first study to quantify the stigma faced by people with TD in a variety of professional and social situations will also be shared.
“These new data add to our understanding of the risk-benefit profile of AUSTEDO in tardive dyskinesia,” said Daniel McBryan M.D., Senior Vice President, Head of Global Medical Affairs and Pharmacovigilance at Teva Pharmaceuticals. “In addition, we look forward to sharing insights from our research that quantify the professional and social stigma associated with this condition.”
Data to be presented include:
All posters will be presented at the Poster Pavilion on both Friday, October 4 and Saturday, October 5 from 1:30-3:00 p.m. PDT.
- Poster 105: Analysis of AIMS Global Judgment Components (Items 8-10) in Patients With TD: Results From the ARM-TD and AIM-TD Studies
- Poster 115: An Experimental Study to Assess the Professional and Social Consequences of Mild-to-Moderate Tardive Dyskinesia
- Poster 116: An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia
- Poster 117: Impact of Antipsychotic Treatment Switching in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
- Poster 148: Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study
- Poster 158: Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia
- Poster 315: Randomized Withdrawal Study Design to Evaluate the Persistence of the Therapeutic Effect of Deutetrabenazine in the Treatment of Tardive Dyskinesia
